WO2024246867 - USE OF AN OREXIN 2 RECEPTOR AGONIST FOR IMPROVING RESPIRATORY FUNCTION DURING SLEEP
National phase entry is expected:
Publication Number
WO/2024/246867
Publication Date
05.12.2024
International Application No.
PCT/IB2024/055361
International Filing Date
31.05.2024
Title **
[English]
USE OF AN OREXIN 2 RECEPTOR AGONIST FOR IMPROVING RESPIRATORY FUNCTION DURING SLEEP
[French]
UTILISATION D'UN AGONISTE DU RÉCEPTEUR DE L'OREXINE 2 POUR AMÉLIORER LA FONCTION RESPIRATOIRE PENDANT LE SOMMEIL
Applicants **
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventors
KIMURA, Haruhide
YAMADA, Ryuji
Priority Data
63/505,795
02.06.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
* |
| Recordal of a Change of the Applicant's Name/Address | * |
| Type of Assignment | * |
| Applicant's Legal Status | * |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under | * |
| Patent Delivery | * |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2970 | |
| EPO | Filing, Examination, Granting | 18222 | |
| Japan | Filing, Examination, Granting | 2762 | |
| South Korea | Filing, Examination, Granting | 3416 | |
| USA | Filing, Examination, Granting | 6940 |
Total:
34,310
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Disclosed are uses of an orexin type 2 receptor (OX2R) agonist at non-awakening concentrations to treat sleep apnea. Also disclosed are compositions and methods for administering an OX2R agonist to a subject (e.g., mammal) in need thereof at a dose that provides a blood plasma concentration of the OX2R agonist that is at or below the maximum non-awakening blood plasma concentration of the OX2R agonist. Also disclosed are compositions and methods for treating sleep apnea in a subject in need thereof by maintaining the blood plasma concentration of an OX2R agonist following administration which is at or below the maximum non-awakening concentration of the OX2R agonist.[French]
Sont divulguées des utilisations d'un agoniste du récepteur de l'orexine de type 2 (OX2R) à des concentrations de non-éveil pour traiter l'apnée du sommeil. Sont également divulguées des compositions et des méthodes d'administration d'un agoniste de l'OX2R à un sujet (par exemple, un mammifère) en ayant besoin à une dose qui assure une concentration dans le plasma sanguin de l'agoniste de l'OX2R qui est inférieure ou égale à la concentration de non-éveil maximale dans le plasma sanguin de l'agoniste de l'OX2R. Sont également divulguées des compositions et des méthodes de traitement de l'apnée du sommeil chez un sujet en ayant besoin par maintien de la concentration dans le plasma sanguin d'un agoniste de l'OX2R après administration qui est inférieure ou égale à la concentration de non-éveil maximale de l'agoniste de l'OX2R.